Biovaxys Technology (BIOV.CN) Stock Price

Biovaxys Technology Price

CSE·CLOSED
0.07
​
Market closed

Biovaxys Technology stock price

Access this data via the Eulerpool API

Biovaxys Technology business model & stock analysis

BioVaxys Technology Corp. is a clinical stage biotechnology company. The company is headquartered in Etobicoke, Ontario. The company went IPO on 2018-11-21. The firm is engaged in developing viral and oncology vaccine platforms and immuno-diagnostics. The firm is developing BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer and is also a United States distributor of a portfolio of OTC female reproductive health products marketed in the European Union from Barcelona-based Procare Health Iberia. The firm is also exploring vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its HapTenix platform through academic and other collaborations.

Frequently asked questions about Biovaxys Technology

Converted at the current exchange rate, the Biovaxys Technology share trades at 0.04 EUR (0.07 CAD).

The Biovaxys Technology share (BIOV.CN) is listed on 4 stock exchanges, including: Frankfurt (5LB.F), München (5LB.MU).

The revenue cannot currently be calculated for Biovaxys Technology.

The profit cannot currently be calculated for Biovaxys Technology.

The P/E ratio cannot be calculated for Biovaxys Technology at the moment.

The P/S cannot be calculated for Biovaxys Technology currently.

The Eulerpool Quality Score for Biovaxys Technology is 2/10.

The ISIN of Biovaxys Technology is CA09076M2004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biovaxys Technology is A2QE16. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biovaxys Technology is BIOV.CN. The ticker symbol is used to trade Biovaxys Technology shares on the stock exchange.

Fair ValueTerminal
0.06 CAD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website biovaxys.com
Country
Currency
CAD
Initial public offering
Nov 21, 2018
ISIN
CA09076M2004
Cusip
09076M101
Market capitalization
3.09 M CADMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.38
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
205.97 %
Last updated Oct 10, 2026, 7:28 PM

Biovaxys Technology Peer Group

Biovaxys Technology Ticker

CNQ · BIOV.CNFRANKFURT · 5LB.FMUNICH · 5LB.MUOTC · BVAXF